Biocompatibility study of glycofurol in rat brains

Experimental Biology and Medicine

Volumn 236, Issue 1, 2011, Pages 77-83

  Boongird, Atthaporn ^a   Nasongkla, Norased ^b   Hongeng, Suradej ^a   Sukdawong, Nongyao ^b   Sa Nguanruang, Waridtha ^c   Larbcharoensub, Noppadol ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Biocompatibility; Brain; Drug delivery; Glycofurol; Histopathology; Stereotactic surgery

Indexed keywords

GLYCOFUROL; PHOSPHATE BUFFERED SALINE; SOLVENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCOMPATIBILITY; BRAIN; BRAIN CORTEX; BRAIN TISSUE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; GLIOSIS; HEMATOLOGICAL PARAMETERS; HISTOPATHOLOGY; INFLAMMATION; MACROPHAGE; MALE; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NEUTROPHIL; NONHUMAN; RAT; TISSUE REACTION;

ANIMALS; BIOCOMPATIBLE MATERIALS; BRAIN; DRUG DELIVERY SYSTEMS; ERYTHROCYTE COUNT; ERYTHROCYTE INDICES; HEMATOCRIT; HEMOGLOBINS; INJECTIONS, INTRAVENTRICULAR; LEUKOCYTE COUNT; MALE; MATERIALS TESTING; PLATELET COUNT; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 78751510756     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1258/ebm.2010.010219     Document Type: Article

References (28)

1. Huynh GH, Deen DF, Szoka JFC. Barriers to carrier mediated drug and gene delivery to brain tumors. J Control Release 2006;110:236-59
2. Gabathuler R. Blood-brain barrier transport of drugs for the treatment of brain diseases. CNS Neurol Disord - Drug Targets 2009;8:195-204
3. Abbott NJ. Inflammatory mediators and modulation of blood-brain barrier permeability. Cell Mol Neurobiol 2000;20:131-47
4. Bart J, Groen HJM, Hendrikse NH, van der Graaf WTA, Vaalburg W, de Vries EGE. The blood-brain barrier and oncology: new insights into function and modulation. Cancer Treat Rev 2000;26:449-62
5. Wu D, Pardridge WM. Blood-brain barrier transport of reduced folic acid. Pharm Res 1999;16:415-9
6. Steiniger SC, Kreuter J, Khalansky AS, Skidan IN, Bobruskin AI, Smirnova ZS, et al. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer 2004;109:759-67
7. Laske DW, Youle RJ, Oldfield EH. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 1997;3:1362-8
8. Taira T, Steven L, Nicholas D. S, Adrian M. O. Intrathecal administration of GABA agonists in the vegetative state. Progr Brain Res 2009;177:317-28
9. Mottolese C, Stan H, Hermier M, Berlier P, Convert J, Frappaz D, et al. Intracystic chemotherapy with bleomycin in the treatment of craniopharyngiomas. Childs Nerv Syst 2001;17:724-30
10. Takahashi H, Yamaguchi F, Teramoto A. Long-term outcome and reconsideration of intracystic chemotherapy with bleomycin for craniopharyngioma in children. Childs Nerv Syst 2005;21:701-4
11. Halliday AJ, Cook MJ. Polymer-based drug delivery devices for neurological disorders. CNS Neurol Disord Drug Targets 2009;8(3):205-21
12. Dang W, Daviau T, Brem H. Morphological characterization of polyanhydride biodegradable implant gliadela during in vitro and in vivo erosion using scanning electron microscopy. Pharm Res 1996;13:683-91
13. Dang W, Daviau T, Ying P, Zhao Y, Nowotnik D, Clow CS, et al. Effects of GLIADEL@ wafer initial molecular weight on the erosion of wafer and release of BCNU. J Control Release 1996;42:83-92
14. Mary PW, Janet AT, Henry B, Robert L. In vivo versus in vitro degradation of controlled release polymers for intracranial surgical therapy. J Biomed Mater Res 1994;28:387-95
15. Madrid Y, Langer LF, Brem H, Langer R. New directions in the delivery of drugs and other substances to the central nervous system. Adv Pharmacol 1991;22:299-324
16. Brem H, Langer R. Polymer-based drug delivery to the brain. Sci Med 1996;3:52-61
17. Attenello F, Mukherjee D, Datoo G, McGirt M, Bohan E, Weingart J, et al. Use of Gliadel (BCNU) Wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann Surg Oncol 2008;15:2887-93.
18. Gallego JM, Barcia JA, Barcia-Mariño C. Fatal outcome related to carmustine implants in glioblastoma multiforme. Acta Neurochir 2007;149:261-5
19. Kim S, Jung S-H, Cho C-W. Physicochemical studies of a newly synthesized molecule, 6-methyl-3-phenethyl-3,4-dihydro-1Hquinazoline- 2-thione (JSH18) for topical formulations. Arch Pharmacol Res 2008;31:1363-8
20. Hjortkjaer RK, Bechgaard E, Gizurarson S, Suzdak C, McDonald P, Greenough RJ. Single- and repeated-dose local toxicity in the nasal cavity of rabbits after intranasal administration of different glycols for formulations containing benzodiazepines. J Pharm Pharmacol 1999;51:377-83
21. Ivaturi VD, Riss JR, Kriel RL, Siegel RA, Cloyd JC. Bioavailability and tolerability of intranasal diazepam in healthy adult volunteers. Epilepsy Res 2009;84(2-3):120-6
22. Eliaz R, Szoka F. Robust and prolonged gene expression from injectable polymeric implants. Gene Ther 2002;9:1230-7
23. Bagger MA, Nielsen HW, Bechgaard E. Nasal bioavailability of peptide T in rabbits: absorption enhancement by sodium glycocholate and glycofurol. Eur J Pharm Sci 2001;14:69-74
24. Rom EE, Joseph K. Characterization of a polymeric PLGA-injectable implant delivery system for the controlled release of proteins. J Biomed Mater Res Part A 2000;50:388-96
25. Ola D, Pamela S, Evan DK. Bioavailabilities of rectal and oral methadone in healthy subjects. Br J Clin Pharmacol 2004;58:156-62
26. Dudeck O, Jordan O, Hoffmann KT, Okuducu AF, Tesmer K, Kreuzer-Nagy T, et al. Organic solvents as vehicles for precipitating liquid embolics: a comparative angiotoxicity study with superselective injections of swine rete mirabile. AJNR Am J Neuroradiol 2006;27:1900-6
27. Wade A, Weller PJ, eds. Handbook of Pharmaceutical Excipients. 2nd edn. Washington, DC: American Pharmaceutical Association, 1994
28. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. 5th edn. Burlington: Elsevier Academic Press, 2005